Lloyd George W.
Known title: EVP, Investments & GCCIK: 0001814899
Associated companies
Transaction History
| RPRX | ▼ Sell | Open Market | 30,654 | $1.2M | 12/18/2025 | View on chart |
| RPRX | ▼ Sell | Open Market | 79,346 | $3.1M | 12/17/2025 | View on chart |
| RPRX | ▼ Sell | Open Market | 110,000 | $4.4M | 12/3/2025 | View on chart |
| RPRX | ▼ Sell | Open Market | 47,798 | $1.8M | 11/19/2025 | View on chart |
| RPRX | ▼ Sell | Open Market | 4,628 | $181K | 11/19/2025 | View on chart |
| RPRX | ▼ Sell | Open Market | 47,401 | $1.8M | 11/19/2025 | View on chart |
| RPRX | ▼ Sell | Open Market | 4,599 | $179K | 11/19/2025 | View on chart |
| RPRX | ▼ Sell | Open Market | 25,530 | $977K | 11/19/2025 | View on chart |
| RPRX | ▼ Sell | Open Market | 2,470 | $96K | 11/19/2025 | View on chart |
| RPRX | ▼ Sell | Open Market | 2,770 | $106K | 11/19/2025 | View on chart |
| RPRX | ▼ Sell | Open Market | 230 | $9K | 11/19/2025 | View on chart |
| RPRX | ▲ Buy | Grant | 6,168 | $0 | 11/5/2025 | View on chart |
| RPRX | ▲ Buy | Grant | 3,696 | $0 | 8/6/2025 | View on chart |
| RPRX | ▲ Buy | Grant | 48,646 | $0 | 5/8/2025 | View on chart |
| RPRX | ▼ Sell | Other | 50,000 | $0 | 11/13/2023 | View on chart |
| RPRX | ▼ Sell | Other | 100,000 | $0 | 11/13/2023 | View on chart |
| RPRX | ▼ Sell | Open Market | 79,099 | $2.7M | 6/6/2023 | View on chart |
| RPRX | ▼ Sell | Open Market | 19,215 | $644K | 6/5/2023 | View on chart |
| RPRX | ▼ Sell | Open Market | 1,686 | $57K | 6/2/2023 | View on chart |
| RPRX | ▼ Sell | Open Market | 92,221 | $3.1M | 6/2/2023 | View on chart |
| RPRX | ▼ Sell | Open Market | 12,779 | $473K | 3/29/2023 | View on chart |
| RPRX | ▼ Sell | Open Market | 100,000 | $3.7M | 3/28/2023 | View on chart |
| RPRX | ▼ Sell | Open Market | 25,000 | $932K | 2/23/2023 | View on chart |
| RPRX | ▼ Sell | Open Market | 14,469 | $625K | 11/22/2022 | View on chart |
| RPRX | ▼ Sell | Open Market | 1,900 | $82K | 11/22/2022 | View on chart |
| RPRX | ▼ Sell | Open Market | 3,100 | $134K | 11/21/2022 | View on chart |
| RPRX | ▼ Sell | Open Market | 20,531 | $885K | 11/21/2022 | View on chart |
| RPRX | ▼ Sell | Open Market | 25,000 | $1.1M | 11/10/2022 | View on chart |
| RPRX | ▼ Sell | Open Market | 25,000 | $1.1M | 11/10/2022 | View on chart |
| RPRX | ▼ Sell | Open Market | 8,995 | $395K | 8/10/2022 | View on chart |
| RPRX | ▼ Sell | Open Market | 11,859 | $521K | 8/9/2022 | View on chart |
| RPRX | ▼ Sell | Open Market | 4,046 | $178K | 7/28/2022 | View on chart |
| RPRX | ▼ Sell | Open Market | 25,000 | $1.1M | 7/27/2022 | View on chart |
| RPRX | ▼ Sell | Open Market | 100 | $4K | 7/27/2022 | View on chart |
| RPRX | ▼ Sell | Open Market | 5,443 | $234K | 7/26/2022 | View on chart |
| RPRX | ▼ Sell | Open Market | 13,886 | $599K | 7/26/2022 | View on chart |
| RPRX | ▼ Sell | Open Market | 19,557 | $839K | 7/25/2022 | View on chart |
| RPRX | ▼ Sell | Open Market | 11,114 | $478K | 7/25/2022 | View on chart |
| RPRX | ▼ Sell | Open Market | 13,974 | $570K | 5/27/2022 | View on chart |
| RPRX | ▼ Sell | Open Market | 86,026 | $3.5M | 5/26/2022 | View on chart |
| RPRX | ▼ Sell | Open Market | 100,000 | $4.0M | 5/23/2022 | View on chart |
| RPRX | ▼ Sell | Open Market | 84,148 | $3.6M | 11/17/2021 | View on chart |
| RPRX | ▼ Sell | Open Market | 72,659 | $3.1M | 11/16/2021 | View on chart |
| RPRX | ▼ Sell | Open Market | 27,341 | $1.2M | 11/16/2021 | View on chart |
| RPRX | ▼ Sell | Open Market | 65,852 | $2.8M | 11/16/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Royalty Pharma Declares Q4 2026 Dividend
Royalty Pharma announced its fourth-quarter 2026 dividend, a routine move that supports its status as a consistent income provider with a yield near 3%. Recent commentary also highlights the company's valuation metrics, noting that its multiples may offer an attractive risk-reward balance for some market participants. The stock currently trades within its 52-week range, with analysts maintaining a consensus target price above current levels.
Royalty Pharma Declares Q4 2026 Dividend. Royalty Pharma announced its fourth-quarter 2026 dividend, a routine move that supports its status as a consistent income provider with a yield near 3%. Recent commentary also highlights the company's valuation metrics, noting that its multiples may offer an attractive risk-reward balance for some market participants. The stock currently trades within its 52-week range, with analysts maintaining a consensus target price above current levels.